Dang Qin, Shao Bo, Zhou Quanbo, Chen Chen, Guo Yaxin, Wang Guixian, Liu Jinbo, Kan Quancheng, Yuan Weitang, Sun Zhenqiang
Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Front Oncol. 2021 Jun 15;11:681781. doi: 10.3389/fonc.2021.681781. eCollection 2021.
Cancer metastasis is a symptom of adverse prognosis, a prime origin of therapy failure, and a lethal challenge for cancer patients. -methyladenosine (mA), the most prevailing modification in messenger RNAs (mRNAs) and non-coding RNAs (ncRNAs) of higher eukaryotes, has attracted increasing attention. Growing studies have verified the pivotal roles of mA methylation in controlling mRNAs and ncRNAs in diverse physiological processes. Remarkably, recent findings have showed that aberrant methylation of mA-related RNAs could influence cancer metastasis. In this review, we illuminate how mA modifiers act on mRNAs and ncRNAs and modulate metastasis in several cancers, and put forward the clinical application prospects of mA methylation.
癌症转移是不良预后的症状、治疗失败的主要根源，也是癌症患者面临的致命挑战。N6-甲基腺苷（m6A）是高等真核生物信使核糖核酸（mRNA）和非编码核糖核酸（ncRNA）中最普遍的修饰，已引起越来越多的关注。越来越多的研究证实了m6A甲基化在多种生理过程中对mRNA和ncRNA的调控起着关键作用。值得注意的是，最近的研究结果表明，与m6A相关的RNA异常甲基化可能影响癌症转移。在本综述中，我们阐明了m6A修饰因子如何作用于mRNA和ncRNA并调节几种癌症中的转移，并提出了m6A甲基化的临床应用前景。
